Extractumpharma

What Extractumpharma does

ExtractumPharma zrt. is a Hungarian-owned, Budapest-headquartered generic pharmaceutical manufacturer founded in 1993 by Nemes József and Dr. Antal Balázs. The company develops, manufactures, and distributes human pharmaceutical products across eight therapeutic areas (cardiovascular, pain management, addictology, allergy, ophthalmology, cough suppression, neuropathy, and additional categories), offering both prescription and OTC medications including branded products such as Aspicont, Dexoblok, DrotavEP, VenoprotEP, and AllistilEP. Manufacturing operations are conducted at the company's Kunfehértó facility in Bács-Kiskun County, which produces solid dosage forms (tablets, film-coated tablets, capsules) with batch sizes from 0.5 kg to 250 kg and annual capacity exceeding one billion tablets, supported by ICH-compliant analytical laboratories and stability chambers at 25°C/60%RH, 30°C/65%RH, and 40°C/75%RH.

The company operates a multi-revenue-stream business model combining branded generic pharmaceutical sales distributed through Hungarian pharmaceutical wholesalers and exported via subsidiaries in Serbia (Subotica) and Italy (Milan) plus distributor networks across Denmark, Sweden, Romania, Costa Rica, Sri Lanka, Saudi Arabia, CIS countries, and Vietnam. Beyond product sales, ExtractumPharma monetizes dossier license rights to domestic and international partners, provides contract manufacturing and packaging services for solid dosage forms (including blister ALU/ALU, ALU/PVC, PVdC and container packaging), manufactures and distributes investigational medicinal products (IMP) for clinical trials including narcotics-handling capabilities, and offers pharmaceutical development services covering preformulation, formulation, scale-up, analytical method development, and registration documentation. The company holds EU GMP certification (2021), Hungarian pharmaceutical manufacturing license (2022), wholesale distribution license covering allopathic, narcotics, immunological, and cold-chain products, and a narcotics facility license (2020).

The company's regulatory footprint, multi-decade operational track record, and continuous EU-funded capacity expansion (including a 2025 National Champions grant for production scale-up and AI infrastructure) position it as an established mid-sized player in Central European generic pharmaceuticals. Distribution is supported by a nationwide physician and pharmacy visit network targeting doctors, healthcare professionals, and patients, with marketing regulated under the Hungarian Pharmaceutical Communication Code of Ethics. Headcount of 245-250 employees with 25% tenured beyond 10 years reflects institutional manufacturing expertise, and the company's relationship with international partners as a representative, contract manufacturer, and dossier licensor provides additional revenue optionality beyond its own branded product portfolio.

Name

Extractumpharma

Legal name

ExtractumPharma Gyógyszergyártó, Forgalmazó és Szaktanácsadó zártkörűen működő részvénytársaság

Website

https://expharma.hu

Company type

Private

Founded year

1993

Operating status

Operating

Headcount range

101–250 employees

Short description

ExtractumPharma is a Hungarian-owned generic pharmaceutical manufacturer founded in 1993, developing, producing, and distributing prescription and OTC medicines across 8 therapeutic areas. It serves Hungarian pharmacies via wholesalers and exports to 9 countries, offering contract manufacturing, dossier licensing, and clinical trial material services.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC)

akta.pro secondary industry

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Generic pharmaceutical manufacturing
• Contract manufacturing services
• Pharmaceutical wholesale distribution
• Solid dosage form production
• Drug development services

Headquarters

HQ city

Budapest

HQ country

Hungary

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Generic Pharmaceutical Product Sales: Development, manufacturing and distribution of generic human pharmaceutical products across 8 therapeutic areas including cardiovascular, pain management, addiction treatment, allergy, ophthalmology, cough suppression, and neuropathy treatments. Products sold as both prescription and over-the-counter medications through pharmaceutical wholesalers to pharmacies.
2. License Rights Sales: Sales of dossier license rights for proprietary and partner-developed generic products to domestic and export markets, primarily EU member states and Eastern European countries.
3. Contract Manufacturing Services: Pharmaceutical contract manufacturing and packaging services for solid dosage forms (tablets, film-coated tablets, capsules) from small-scale (0.5 kg) to industrial scale (250 kg), with blister and bottle packaging capabilities.
4. Clinical Trial Material Services: Manufacturing, packaging, and full logistics for investigational medicinal products (IMP) including those requiring narcotic handling, import licenses, customs clearance, and complete administration for clinical trials.
5. Pharmaceutical Development Services: Drug development services including preformulation, formulation, scale-up, manufacturing optimization, validation, analytical method development, and registration documentation preparation.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

ExtractumPharma is a Hungarian family-owned pharmaceutical company that develops, manufactures, and distributes generic human pharmaceutical products in solid dosage forms (tablets, film-coated tablets, capsules) across eight therapeutic areas including cardiovascular, pain management, addiction treatment, allergy, ophthalmology, cough suppression, and neuropathy. In addition to its own OTC and prescription product portfolio, the company provides contract manufacturing, pharmaceutical packaging, investigational medicinal product (IMP) supply, drug development, analytical laboratory, and dossier licensing services to domestic and international pharmaceutical partners.

Product overview

ExtractumPharma is a Hungarian-owned generic pharmaceutical manufacturer offering a portfolio of prescription and OTC human medications across 8 therapeutic areas, alongside comprehensive pharmaceutical services. OTC products include Aspicont (pain relief), Dexoblok (NSAID), DrotavEP (antispasmodic), VenoprotEP (venoprotective), and AllistilEP (antihistamine gel). Prescription products cover cardiovascular, pain management, addictology, allergy, ophthalmology, cough, and neuropathy treatments. Services include contract manufacturing (solid dosage forms, 0.5-250kg batches), pharmaceutical packaging (blister and container), IMP manufacturing/distribution, drug development (formulation, scale-up), analytical laboratory services, regulatory/dossier services, license rights sales, and wholesale distribution. The company operates GMP-certified manufacturing facilities in Kunfehértó with export presence in Denmark, Sweden, Romania, Serbia, Costa Rica, Sri Lanka, Saudi Arabia, CIS countries, and Vietnam.

Differentiator

Problem solved

Functional benefit

Products and services

• Aspicont tabletta OTC pain relief tablet containing acetylsalicylic acid with caffeine, indicated for headache, toothache, musculoskeletal pain, and menstrual pain in adults and children over 16. Available in 10 and 20 tablet packs.
• Dexoblok 25 mg filmtabletta OTC film-coated tablet containing dexketoprofen for short-term treatment of mild to moderate pain including musculoskeletal pain, menstrual pain, and toothache. Available in 10, 20, and 30 tablet packs.
• DrotavEP 40 mg tabletta OTC tablet containing drotaverin for relieving smooth muscle and nerve-derived spasms of the kidney/bladder, gallbladder/bile duct, and gastrointestinal tract, as well as menstrual cramps and headaches. Pack of 30 tablets.
• VenoprotEP filmtabletta OTC venoprotective film-coated tablet containing micronized diosmin and hesperidin bioflavonoids. Inhibits varicose vein dilation, increases capillary resistance, and improves chronic venous disease symptoms. Available in 30 and 60 tablet packs.
• AllistilEP gél OTC topical gel containing dimetindene for treatment of sunburn, insect bites, superficial burns, and itching from skin conditions. Antihistamine effect with immediate analgesic action and cooling sensation. 50g tube.
• Generic Prescription Pharmaceutical Portfolio Prescription pharmaceutical product lines covering cardiovascular treatments (antihypertensives and vascular disease prevention), pain management (simple analgesics, NSAIDs, weak and strong opioids for neuropathic and spasm-related pain), addictology (narcotic medications for opioid replacement therapy), allergy (second-generation antihistamines and topical formulations), ophthalmology (glaucoma and combination infection/inflammation treatments), cough suppression (syrups and tablets for adults and children), and neuropathy (causal and symptomatic treatments across severity levels).
• Contract Manufacturing Services Solid dosage form contract manufacturing services for pharmaceutical partners with batch sizes from 0.5 kg to 250 kg and annual capacity exceeding one billion tablets. Includes pilot, mid-scale, and industrial production lines.
• Pharmaceutical Packaging Services Solid dosage form packaging services including blister packaging (ALU/ALU, ALU/PVC, PVdC), container packaging (glass or plastic), labeling, cartoning, GS1 serialization, and bundling.
• Investigational Medicinal Product (IMP) Manufacturing, Packaging, and Distribution cGMP-compliant IMP manufacturing, primary and secondary packaging, relabeling, and full logistics including import licenses, customs clearance, and destruction for clinical trial sponsors. Includes narcotics handling capability for controlled-substance trials.
• Drug Development Services Generic drug development including preformulation, formulation, scale-up, manufacturing optimization, validation, and process optimization. Includes technology and analytical transfers for purchased registration dossiers.
• Analytical Laboratory Services Analytical method development and validation including quantitative and qualitative determinations, impurity profiling, stability studies, and release testing for registration batches. ICH-compliant stability chambers operating at 25°C/60%RH, 30°C/65%RH, and 40°C/75%RH with validated continuous monitoring.
• Registration and Dossier Services Registration documentation preparation, compilation, and maintenance including evaluation of existing documentation, complete or partial dossier assembly, registration procedures with local authorities, and marketing authorization acquisition.
• License Rights Sales Sales of license rights for own-developed dossiers and partner-developed dossiers for domestic and export markets, primarily targeting EU member states and Eastern European countries.
• Pharmaceutical Wholesale Distribution Wholesale distribution of pharmaceutical products including allopathic products, narcotics/psychotropic substances, immunological drugs, and cold-chain products under company-held wholesale distribution license.

Quantifiable outcome

• Annual manufacturing capacity exceeding 1 billion tablets
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators5 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• KRKA: Slovenian generic pharmaceutical manufacturer with vertically integrated API-to-finished-dose operations and strong Central/Eastern European market share. Comparable in generic portfolio breadth, contract manufacturing services, and export-driven growth model to non-EU markets.
• EGIS Pharmaceuticals: Hungarian generic and specialty pharmaceutical manufacturer owned by Servier. Direct peer across cardiovascular, CNS, and women's health generics, with comparable EU GMP-certified manufacturing operations and Eastern European export presence.
• Gedeon Richter: Hungarian-headquartered pharmaceutical manufacturer with both branded and generic operations across multiple therapeutic areas. Direct peer given shared domestic Hungarian manufacturing base, generic product overlap, and export footprint to Central/Eastern Europe.
• Zentiva: Czech-based European generic pharmaceutical manufacturer (formerly Sanofi generics unit). Direct peer in solid dosage form generics across cardiovascular, pain, and CNS with extensive Eastern European distribution — closely comparable therapeutic area coverage and business model.

Regional players

• Alkaloid: North Macedonian pharmaceutical manufacturer with generics, OTC, and chemical divisions. Comparable as a regional Balkan peer with similar therapeutic area breadth and EU export ambitions, though smaller in scale than ExtractumPharma.
• Polpharma: Poland's largest pharmaceutical manufacturer with strong generics portfolio. Comparable as a Central European generic peer with similar contract manufacturing capabilities and export orientation, though operating from a larger Polish manufacturing base.

Broad incumbents

• Stada Arzneimittel: European-focused generic and consumer healthcare company with extensive Central European distribution. Broad incumbent peer competing across multiple therapeutic areas with significantly larger scale and portfolio breadth than ExtractumPharma.
• Sandoz: Novartis' standalone generics division and global leader in off-patent medicines. Broad incumbent peer that competes with ExtractumPharma's generic molecules in EU and emerging markets, while offering biosimilars and complex generics beyond the regional player's reach.
• Teva Pharmaceutical Industries: Global generic pharmaceutical leader with the broadest generic portfolio worldwide. Broad incumbent peer — ExtractumPharma competes in many of the same molecules at a regional level while Teva operates across the full global generic value chain.

Emerging players

• Xellia Pharmaceuticals: Specialty pharmaceutical company focused on anti-infectives and injectable generics. Emerging player peer relevant through overlap in injectables/complex generics manufacturing, sterile manufacturing expertise, and focus on difficult-to-formulate molecules — though operating in a different therapeutic vertical.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/aspicont
• LinkedInlinkedin.com/company/extractumpharma-zrt.

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Extractumpharma